| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
During the last three months, 5 analysts shared their evaluations of BrightSpring Health (NASDAQ:BTSG), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $32.6, a high estimate of $35.00, and a low estimate of $31.00. This current average reflects an increase of 19.41% from the previous average price target of $27.30.
The analysis of recent analyst actions sheds light on the perception of BrightSpring Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ann Hynes | Mizuho | Raises | Outperform | $32.00 | $26.00 |
| Erin Wright | Morgan Stanley | Raises | Overweight | $32.00 | $25.00 |
| A.J. Rice | UBS | Raises | Buy | $35.00 | $31.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $33.00 | $27.00 |
| Joanna Gajuk | B of A Securities | Raises | Buy | $31.00 | $27.50 |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of BrightSpring Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on BrightSpring Health analyst ratings.
BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services and others. It generates the majority of its revenue from the Pharmacy Solutions segment.
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: BrightSpring Health displayed positive results in 3M. As of 30 June, 2025, the company achieved a solid revenue growth rate of approximately 29.1%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: BrightSpring Health's net margin excels beyond industry benchmarks, reaching 0.9%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.64%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.48%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: BrightSpring Health's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.56, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BTSG
